Stephanie Schorge

Stephanie Schorge

Auto-generated profile, based on publicly available information

Stephanie Schorge

Department of Neuroscience, Physiology and Pharmacology, University College London, Gower Street, London WC1E 6BT, UK

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
STSarah K. Tate
Sarah K. Tate
CDChantal Depondt
Chantal Depondt
SSSanjay M. Sisodiya
Sanjay M. Sisodiya
GCGianpiero L. Cavalleri
Gianpiero L. Cavalleri
SSStephanie Schorge
Stephanie Schorge
DGDavid B. Goldstein
David B. Goldstein
Phenytoin and carbamazepine are effective and inexpensive anti-epileptic drugs (AEDs). As with many AEDs, a broad range of doses is used, with the final “maintenance” dose normally determined by trial and error. Although many genes could influence response to these medicines, there are obvious candidates. Both drugs target the α-subunit of the sodium channel, encoded by theSCNfamily of genes. Phenytoin is principally metabolized by CYP2C9, and both are probable substrates of the drug transporter P-glycoprotein. We therefore assessed whether variation in these genes associates with the clinical use of carbamazepine and phenytoin in cohorts of 425 and 281 patients, respectively. We report that a known functional polymorphism inCYP2C9is highly associated with the maximum dose of phenytoin (P= 0.0066). We also show that an intronic polymorphism in theSCN1Agene shows significant association with maximum doses in regular usage of both carbamazepine and phenytoin (P= 0.0051 andP= 0.014, respectively). This polymorphism disrupts the consensus sequence of the 5′ splice donor site of a highly conserved alternative exon (5N), and it significantly affects the proportions of the alternative transcripts in individuals with a history of epilepsy. These results provide evidence of a drug target polymorphism associated with the clinical use of AEDs and set the stage for a prospective evaluation of how pharmacogenetic diagnostics can be used to improve dosing decisions in the use of phenytoin and carbamazepine. Although the case made here is compelling, our results cannot be considered definitive or ready for clinical application until they are confirmed by independent replication.

21 November 2012 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
RWRob Wykes
Rob Wykes
JHJoost H. Heeroma
Joost H. Heeroma
LMLaura Mantoan
Laura Mantoan
KZKaiyu Zheng
Kaiyu Zheng
DMDouglas C. MacDonald
Douglas C. MacDonald
DKDimitri Michael Kullmann
Dimitri Michael Kullmann
Light-activated gene therapy acutely suppresses seizures, and gene therapy with a potassium channel prevents epileptogenesis and treats established epilepsy in a rodent model.

3 September 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
TSTommy Stödberg
Tommy Stödberg
AMAmy McTague
Amy McTague
ARArnaud Ruiz
Arnaud Ruiz
HHHiromi Hirata
Hiromi Hirata
JZJuan Zhen
Juan Zhen
MKManju A Kurian
Manju A Kurian
The potassium-chloride co-transporter KCC2, encoded by SLC12A5, plays a fundamental role in fast synaptic inhibition by maintaining a hyperpolarizing gradient for chloride ions. KCC2 dysfunction has been implicated in human epilepsy, but to date, no monogenic KCC2-related epilepsy disorders have been described. Here we show recessive loss-of-function SLC12A5 mutations in patients with a severe infantile-onset pharmacoresistant epilepsy syndrome, epilepsy of infancy with migrating focal seizures (EIMFS). Decreased KCC2 surface expression, reduced protein glycosylation and impaired chloride extrusion contribute to loss of KCC2 activity, thereby impairing normal synaptic inhibition and promoting neuronal excitability in this early-onset epileptic encephalopathy.

15 February 2003 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
SSStephanie Schorge
Stephanie Schorge
DCDavid Colquhoun
David Colquhoun
The subunits that compose eukaryotic glutamate ion channel receptors have three transmembrane domains (TMs) and terminate with intracellular tails that are important for controlling channel expression and localization. Truncation of NMDA receptor subunits before the final TM showed that this TM and intracellular tail region are necessary to form functional channels. However, it is shown here that these truncated subunits may be partially rescued by coexpressing the final TM and tail as a separate protein. The whole-cell currents so produced are somewhat lower than with full-length subunits, and they do not show the sag characteristic of currents from channels containing NR1 and NR2A subunits in the continued presence of an agonist. In addition, these truncated subunits were joined to full-length subunits to generate tandems. The functional expression of these tandems confirmed the tetrameric structure of NMDA receptors and also suggested that the subunits making up NMDA receptors are arranged as a dimer of dimers in the receptors with a 1-1-2-2 orientation of the subunits in the channel, and not in an alternating pattern of subunits around the pore. These results may redirect future studies into the mechanism of binding and gating in these receptors toward schemes including dimers, and may also be relevant to studies of glutamate receptor ion channels in general.

5 May 2009 in Neurology
Verified
Journal Article
Closed access
PDF file
EME. Matthews
E. Matthews
RLR. Labrum
R. Labrum
MSM. G. Sweeney
M. G. Sweeney
RSR. Sud
R. Sud
AHA. Haworth
A. Haworth
MHM. G. Hanna
M. G. Hanna
Background: Several missense mutations of CACNA1S and SCN4A genes occur in hypokalemic periodic paralysis. These mutations affect arginine residues in the S4 voltage sensors of the channel. Approximately 20% of cases remain genetically undefined. Methods: We undertook direct automated DNA sequencing of the S4 regions of CACNA1S and SCN4A in 83 cases of hypokalemic periodic paralysis. Results: We identified reported CACNA1S mutations in 64 cases. In the remaining 19 cases, mutations in SCN4A or other CACNA1S S4 segments were found in 10, including three novel changes and the first mutations in channel domains I (SCN4A) and III (CACNA1S). Conclusions: All mutations affected arginine residues, consistent with the gating pore cation leak hypothesis of hypokalemic periodic paralysis. Arginine mutations in S4 segments underlie 90% of hypokalemic periodic paralysis cases.

27 May 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
Dennis KätzelDennis Kätzel
Dennis Kätzel
ENElizabeth Nicholson
Elizabeth Nicholson
SSStephanie Schorge
Stephanie Schorge
MWMatthew C. Walker
Matthew C. Walker
DKDimitri Michael Kullmann
Dimitri Michael Kullmann
Focal epilepsy is commonly pharmacoresistant, and resective surgery is often contraindicated by proximity to eloquent cortex. Many patients have no effective treatment options. Gene therapy allows cell-type specific inhibition of neuronal excitability, but on-demand seizure suppression has only been achieved with optogenetics, which requires invasive light delivery. Here we test a combined chemical–genetic approach to achieve localized suppression of neuronal excitability in a seizure focus, using viral expression of the modified muscarinic receptor hM4Di. hM4Di has no effect in the absence of its selective, normally inactive and orally bioavailable agonist clozapine-N-oxide (CNO). Systemic administration of CNO suppresses focal seizures evoked by two different chemoconvulsants, pilocarpine and picrotoxin. CNO also has a robust anti-seizure effect in a chronic model of focal neocortical epilepsy. Chemical–genetic seizure attenuation holds promise as a novel approach to treat intractable focal epilepsy while minimizing disruption of normal circuit function in untransduced brain regions or in the absence of the specific ligand.